Featured Research

from universities, journals, and other organizations

Benefits of high-dose vitamin C for ovarian cancer patients

Date:
February 10, 2014
Source:
University of Kansas Cancer Center
Summary:
Researchers have found that a combination of infused vitamin C and conventional chemotherapy stopped ovarian cancer in the laboratory, and reduced chemotherapy-associated toxicity in patients with ovarian cancer.

Scientists at the University of Kansas Medical Center have determined that high doses of vitamin C, administered intravenously with traditional chemotherapy, helped kill cancer cells while reducing the toxic effects of chemotherapy for some cancer patients.

Related Articles


By evaluating the therapy in cells, animals, and humans, the researchers found that a combination of infused vitamin C and the conventional chemotherapy drugs carboplatin and paclitaxel stopped ovarian cancer in the laboratory, and reduced chemotherapy-associated toxicity in patients with ovarian cancer. The results of their study have been published in the journal Science Translational Medicine.

"In the 1970s, ascorbate, or vitamin C, was an unorthodox therapy for cancer. It was safe, and there were anecdotal reports of its clinical effectiveness when given intravenously. But after oral doses proved ineffective in two cancer clinical trials, conventional oncologists abandoned the idea. Physicians practicing complementary and alternative medicine continued to use it, so we felt further study was in order," explains the study's senior author, Qi Chen, Ph.D., Assistant Professor in KU Medical Center's Department of Pharmacology, Toxicology and Therapeutics and the Department of Integrative Medicine. "What we've discovered is that, because of its pharmacokinetic differences, intravenous vitamin C, as opposed to oral vitamin C, kills some cancer cells without harming normal tissues."

The researchers' clinical trial involved 27 patients with newly diagnosed Stage 3 or Stage 4 ovarian cancer. All of the participants received conventional therapy with paclitaxel or carboplatin, while some were also treated with high-dose intravenous vitamin C. Researchers monitored the participants for five years. Those patients who received vitamin C tended to experience fewer toxic effects from the chemotherapy drugs.

In laboratory rodents, the scientists observed that vitamin C was able to kill cancer cells at the concentrations achievable only by intravenous infusion, with no observable toxicity or pathological changes in the liver, kidney or spleen.

Collaborating on the study at KU Medical Center were postdoctoral fellow Yan Ma and graduate student Kishore Polireddy in the Department of Pharmacology, Toxicology and Therapeutics; Jeanne Drisko, M.D., director of the Integrative Medicine program; and Julia Chapman, M.D., associate professor in the Department of Obstetrics and Gynecology. Collaborating with the team was Mark Levine, M.D., at the National Institute of Diabetes and Digestive and Kidney Diseases at the National Institutes of Health.

High-dose vitamin C is currently administered intravenously to thousands of patients by practitioners of complementary and alternative medicine. However, Drisko notes, conventional physicians remain skeptical about its therapeutic benefits. Given this current polarization of thought, the researchers sought to understand the cellular mechanisms by which pharmacologic vitamin C manifests its therapeutic benefit in cancer.

"We aimed to investigate the mechanisms of vitamin C-induced cell death in the laboratory. And in patients with ovarian cancer, we conducted an early phase clinical trial examining safety and toxicity of high dose intravenous vitamin C. We now have a better understanding of vitamin C's anti-cancer action, plus a clear safety profile, and biological and clinical plausibility with a firm foundation to proceed," Drisko says. "Taken together, our data provide strong evidence to justify larger and robust clinical trials to definitively examine the benefit of adding vitamin C to conventional chemotherapy."


Story Source:

The above story is based on materials provided by University of Kansas Cancer Center. Note: Materials may be edited for content and length.


Journal Reference:

  1. Y. Ma, J. Chapman, M. Levine, K. Polireddy, J. Drisko, Q. Chen. High-Dose Parenteral Ascorbate Enhanced Chemosensitivity of Ovarian Cancer and Reduced Toxicity of Chemotherapy. Science Translational Medicine, 2014; 6 (222): 222ra18 DOI: 10.1126/scitranslmed.3007154

Cite This Page:

University of Kansas Cancer Center. "Benefits of high-dose vitamin C for ovarian cancer patients." ScienceDaily. ScienceDaily, 10 February 2014. <www.sciencedaily.com/releases/2014/02/140210135908.htm>.
University of Kansas Cancer Center. (2014, February 10). Benefits of high-dose vitamin C for ovarian cancer patients. ScienceDaily. Retrieved November 28, 2014 from www.sciencedaily.com/releases/2014/02/140210135908.htm
University of Kansas Cancer Center. "Benefits of high-dose vitamin C for ovarian cancer patients." ScienceDaily. www.sciencedaily.com/releases/2014/02/140210135908.htm (accessed November 28, 2014).

Share This


More From ScienceDaily



More Health & Medicine News

Friday, November 28, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Rural India's Low-Cost Sanitary Pad Revolution

Rural India's Low-Cost Sanitary Pad Revolution

AFP (Nov. 28, 2014) — One man hopes his invention -– a machine that produces cheap sanitary pads –- will help empower Indian women. Duration: 01:51 Video provided by AFP
Powered by NewsLook.com
Research on Bats Could Help Develop Drugs Against Ebola

Research on Bats Could Help Develop Drugs Against Ebola

AFP (Nov. 28, 2014) — In Africa's only biosafety level 4 laboratory, scientists have been carrying out experiments on bats to understand how virus like Ebola are being transmitted, and how some of them resist to it. Duration: 01:18 Video provided by AFP
Powered by NewsLook.com
WHO Says Male Ebola Survivors Should Abstain From Sex

WHO Says Male Ebola Survivors Should Abstain From Sex

Newsy (Nov. 28, 2014) — WHO cites four studies that say Ebola can still be detected in semen up to 82 days after the onset of symptoms. Video provided by Newsy
Powered by NewsLook.com
Ebola Leaves Orphans Alone in Sierra Leone

Ebola Leaves Orphans Alone in Sierra Leone

AFP (Nov. 27, 2014) — The Ebola epidemic sweeping Sierra Leone is having a profound effect on the country's children, many of whom have been left without any family members to support them. Duration: 01:02 Video provided by AFP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:

Strange & Offbeat Stories

 

Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins